MedPath

Atropine

Generic Name
Atropine
Brand Names
Atnaa, Atropen, Busulfex, Donnatal, Duodote, Enlon-plus, Isopto Atropine, Lomotil, Minims Atropine Sulphate, Motofen, Phenohytro
Drug Type
Small Molecule
Chemical Formula
C17H23NO3
CAS Number
51-55-8
Unique Ingredient Identifier
7C0697DR9I
Background

Atropine is an alkaloid originally synthesized from Atropa belladonna. It is a racemic mixture of d-and l-hyoscyamine, of which only l-hyoscyamine is pharmacologically active. Atropine is generally available as a sulfate salt and can be administered by intravenous, subcutaneous, intramuscular, intraosseous, endotracheal and ophthalmic methods. Oral atropine is only available in combination products. Atropine is a competitive, reversible antagonist of muscarinic receptors that blocks the effects of acetylcholine and other choline esters. It has a variety of therapeutic applications, including pupil dilation and the treatment of anticholinergic poisoning and symptomatic bradycardia in the absence of reversible causes. Atropine is a relatively inexpensive drug and is included in the World Health Organization List of Essential Medicines.

Indication

The intravenous, intramuscular, subcutaneous, intraosseous and endotracheal use of atropine is indicated for the temporary blockade of severe or life-threatening muscarinic effects. The intramuscular use of atropine in the form of a pen injector is indicated for the treatment of poisoning by susceptible organophosphorus nerve agents having cholinesterase activity as well as organophosphorus or carbamate insecticides in adult and pediatric patients. The ophthalmic use of atropine is indicated for mydriasis, cycloplegia, and penalization of the healthy eye in the treatment of amblyopia.

In combination with difenoxin or diphenoxylate (tablets for oral use), atropine is indicated as adjunctive therapy in the management of acute nonspecific diarrhea.

Associated Conditions
Amblyopia, Atrioventricular Heart-block, Bradycardia, Bronchospasm, Crying, Detrusor Hyperreflexia, Excessive bronchial secretion, Hypertonic uterine contraction, Hypertonicity of the small intestine, Ocular Inflammation, Parkinsonism, Peptic Ulcer, Poisoning by parasympathomimetics (cholinergics), Poisoning caused by mushrooms, Poisoning caused by organophosphate anticholinesterase nerve agents, Poisoning caused by organophosphorus pesticides, Pylorospasm, Rhinorrhoea, Sinus Bradycardia, Spasms, Toxic effect of organophosphate and carbamate, Hypermobility of the colon, Laughing, Life-threatening muscarinic side effects, Muscarinic side effects, Severe muscarinic side effects
Associated Therapies
-

Allogeneic Stem Cell Transplantation Following Chemotherapy in Patients With Hemoglobinopathies

Phase 2
Completed
Conditions
Hemoglobinopathies
Sickle Cell Disease
Thalassemia
First Posted Date
2005-09-12
Last Posted Date
2013-07-30
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
2
Registration Number
NCT00153985
Locations
🇺🇸

Winship Cancer Institute-Emory University, Atlanta, Georgia, United States

🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 3 locations

Effects of Epinephrine and Intravenous (I.V.) Needle on Cardiopulmonary Resuscitation (CPR) Outcome

Phase 2
Completed
Conditions
Cardiac Arrest
Interventions
First Posted Date
2005-07-21
Last Posted Date
2015-05-29
Lead Sponsor
Petter Andreas Steen
Target Recruit Count
904
Registration Number
NCT00121524
Locations
🇳🇴

Ulleval University Hospital, Oslo, Norway

Trial Comparing Daily Atropine Versus Weekend Atropine

Phase 4
Completed
Conditions
Amblyopia
First Posted Date
2004-10-22
Last Posted Date
2010-03-25
Lead Sponsor
Jaeb Center for Health Research
Target Recruit Count
168
Registration Number
NCT00094614
Locations
🇺🇸

Wilmer Eye Institute, Baltimore, Maryland, United States

An Evaluation of Treatment of Amblyopia in Children 7 To <18 Years Old

Phase 3
Completed
Conditions
Amblyopia
First Posted Date
2004-10-22
Last Posted Date
2010-03-24
Lead Sponsor
Jaeb Center for Health Research
Target Recruit Count
507
Registration Number
NCT00094692
Locations
🇺🇸

Wilmer Eye Institute, Baltimore, Maryland, United States

🇺🇸

Pennsylvania College of Optometry, Philadelphia, Pennsylvania, United States

🇺🇸

Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States

Amblyopia (Lazy Eye) Treatment Study

Phase 3
Completed
Conditions
Amblyopia
Anisometropia
Strabismus
First Posted Date
2002-05-22
Last Posted Date
2008-03-04
Lead Sponsor
National Eye Institute (NEI)
Target Recruit Count
20
Registration Number
NCT00001864
Locations
🇺🇸

National Eye Institute (NEI), Bethesda, Maryland, United States

Occlusion Versus Pharmacologic Therapy for Moderate Amblyopia

Phase 3
Completed
Conditions
Amblyopia
Interventions
Device: Eye Patch
Drug: Atropine
First Posted Date
1999-09-24
Last Posted Date
2014-03-06
Lead Sponsor
Jaeb Center for Health Research
Target Recruit Count
419
Registration Number
NCT00000170
Locations
🇺🇸

Wilmer Eye Institute, Baltimore, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath